Wang C.-Y.Lin Y.S.Wang Y.-H.Lai C.-C.HAO-CHIEN WANGChen L.CHONG-JEN YUPerng D.-W.Cheng S.-L.Hsu J.-Y.Hsu W.-H.Tsai Y.-H.Hsiue T.-R.Lin M.-C.Lin H.-I.Wang C.-Y.YEUN-CHUNG CHANGYang U.-C.Chen C.-M.Lin C.-S.Chen L.Wei Y.-F.Chong I.-W.CHUNG-YU CHENOn the behalf of Taiwan Clinical Trial Consortium for Respiratory Diseases (TCORE)2020-08-122020-08-1220191945-4589https://www.scopus.com/inward/record.uri?eid=2-s2.0-85072307003&doi=10.18632%2faging.102217&partnerID=40&md5=2e01c761ae4ca92d8c2382a9db4b8c52https://scholars.lib.ntu.edu.tw/handle/123456789/512188This study aimed to compare the effect of budesonide/formoterol and fluticasone/salmeterol on the risk and outcomes of sepsis in COPD patients. We conducted this study using the Taiwan National Health Insurance Research Database. We included COPD patients prescribed with budesonide/formoterol or fluticasone/salmeterol between 2004 and 2011. Outcomes including sepsis and mortality were measured. 10,267 COPD patients who received fluticasone/salmeterol and 6,844 patients who received budesonide/formoterol were enrolled into this study and then subsequence were adjusted by propensity score weighting. The incidence of sepsis was 5.74 and 4.99 per 100 person-years for the patients receiving fluticasone/salmeterol and budesonide/formoterol, respectively. Fluticasone/salmeterol was associated with higher risk of sepsis (aHR, 1.15; 95%CI, 1.07-1.24) and septic shock (aHR, 1.14; 95%CI, 1.01-1.29) than budesonide/formoterol. Besides, fluticasone/salmeterol was associated with higher risk of death (aHR, 1.090; 95%CI, 1.01-1.18) than budesonide/formoterol. Patients receiving fluticasone/salmeterol had a significant higher risk of sepsis related respiratory organ dysfunction, lower respiratory tract infection, genitourinary tract infection, bacteremia and skin infection. In conclusion, long-term treatment with budesonide/formoterol was associated with lower rates of sepsis and deaths than fluticasone/salmeterol in patients with COPD. ? Wang et al.[SDGs]SDG3beta 2 adrenergic receptor stimulating agent; bronchodilating agent; budesonide plus formoterol; corticosteroid; fluticasone propionate plus salmeterol; chronic obstructive lung disease; female; human; incidence; male; middle aged; sepsis; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Budesonide, Formoterol Fumarate Drug Combination; Female; Fluticasone-Salmeterol Drug Combination; Humans; Incidence; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Sepsisjournal article10.18632/aging.102217315095172-s2.0-85072307003